Minerva Neurosciences, Inc. (NERV): Total Assets
$97.97M
As of 2025-12-31
$95.09M
As of 2026-06-30
+21.2%
3-year compound annual growth
+11.2%
5-year compound annual growth
+1.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $97.97M | +163.8% | 2026-03-11, Balance as of period end |
| 2024-12-31 | $37.14M | -34.7% | 2026-03-11, Balance as of period end |
| 2023-12-31 | $56.90M | +3.3% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $55.09M | -28.6% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $77.12M | +33.8% | 2023-03-08, Balance as of period end |
| 2020-12-31 | $57.63M | -25.6% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $77.50M | -44.3% | 2021-03-08, Balance as of period end |
| 2018-12-31 | $139.14M | -24.3% | 2020-03-09, Balance as of period end |
| 2017-12-31 | $183.70M | +38.2% | 2019-03-12, Balance as of period end |
| 2016-12-31 | $132.94M | +61.0% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $82.58M | +20.6% | 2017-03-13, Balance as of period end |
| 2014-12-31 | $68.45M | +134.6% | 2016-03-14, Balance as of period end |
| 2013-12-31 | $29.17M | n/a | 2015-03-26, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | 2025-12-31 | $97.97M | +163.8% |
| iBio, Inc. (IBIO) | 2026-06-30 | $99.11M | +327.5% |
| Citius Oncology, Inc. (CTOR) | 2025-09-30 | $100.94M | +19.6% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $94.62M | -28.2% |
| Journey Medical Corp (DERM) | 2025-12-31 | $94.59M | +17.9% |
| Relmada Therapeutics, Inc. (RLMD) | 2025-12-31 | $94.00M | +105.2% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $92.11M | +21.0% |
| Tenax Therapeutics, Inc. (TENX) | 2025-12-31 | $104.23M | +7.8% |
| Immix Biopharma, Inc. (IMMX) | 2025-12-31 | $104.84M | +356.9% |
Compare NERV, IBIO, CTOR, ABUS side by side · Screen every company in Pharmaceutical Preparations ↗